Background & aims: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new loci contributing to severe NAFLD by examining rare variants. Methods: We performed whole-exome sequencing in individuals with NAFLD and advanced fibrosis or hepatocellular carcinoma (n=301) and examined the enrichment of likely pathogenic rare variants vs. the general population, followed by validation at gene level. Results: In patients with severe NAFLD, we observed an enrichment of the p.P426L variant (rs143545741 C>T; OR 5.26, 2.1-12.6; p=0.003) of autophagy-related 7 (ATG7), which we characterized as a loss-of-function, vs. the general population, and an enrichment in rare variants affecting the catalytic domain (OR 13.9, 1.9-612; p=0.002). In the UK Biobank cohort, loss-of-function ATG7 variants increased the risk of cirrhosis and hepatocellular carcinoma (OR 3.30, 1.1-7.5 and OR 12.30, 2.6-36, respectively; p<0.001 for both). The low-frequency loss-of-function p.V471A variant (rs36117895 T>C) was also associated with severe NAFLD in the clinical cohort (OR=1.7, 1.2-2.5; p=0.003), predisposed to hepatocellular ballooning (p=0.007) evolving to fibrosis in a Liver biopsy cohort (n=2268), and was associated with liver injury in the UK Biobank (AST levels, p<0.001), with a larger effect in severely obese individuals where it was linked to hepatocellular carcinoma (p=0.009). ATG7 protein localized to periportal hepatocytes, more so in the presence of ballooning. In the Liver Transcriptomic cohort (n=125) ATG7 expression correlated with suppression of the TNFα pathway, which was conversely upregulated in p.V471A carriers. Conclusions: We identified rare and low-frequency ATG7 loss-of-function variants as modifiers of NAFLD progression by impairing autophagy and facilitating ballooning and inflammation. Lay summary: •We found that rare mutations in a gene called autophagy related (ATG7) increase the risk of developing severe liver disease in individuals with dysmetabolism. •These mutations cause an alteration in protein function and impairment of self-renewal of cellular content, leading to liver damage and inflammation.

Rare ATG7 genetic variants predispose patients to severe fatty liver disease / G.A. Baselli, O. Jamialahmadi, S. Pelusi, E. Ciociola, F. Malvestiti, M. Saracino, L. Santoro, A. Cherubini, P. Dongiovanni, M. Maggioni, C. Bianco, F. Tavaglione, A. Cespiati, R.M. Mancina, R. D'Ambrosio, V. Vaira, S. Petta, L. Miele, U. Vespasiani-Gentilucci, A. Federico, J. Pihlajamaki, E. Bugianesi, A.L. Fracanzani, H.L. Reeves, G. Soardo, D. Prati, S. Romeo, L.V. Valenti. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 77:3(2022 Sep), pp. 596-606. [10.1016/j.jhep.2022.03.031]

Rare ATG7 genetic variants predispose patients to severe fatty liver disease

G.A. Baselli;S. Pelusi;F. Malvestiti;A. Cherubini;P. Dongiovanni;A. Cespiati;R. D'Ambrosio;V. Vaira;A.L. Fracanzani;L.V. Valenti
Ultimo
2022

Abstract

Background & aims: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new loci contributing to severe NAFLD by examining rare variants. Methods: We performed whole-exome sequencing in individuals with NAFLD and advanced fibrosis or hepatocellular carcinoma (n=301) and examined the enrichment of likely pathogenic rare variants vs. the general population, followed by validation at gene level. Results: In patients with severe NAFLD, we observed an enrichment of the p.P426L variant (rs143545741 C>T; OR 5.26, 2.1-12.6; p=0.003) of autophagy-related 7 (ATG7), which we characterized as a loss-of-function, vs. the general population, and an enrichment in rare variants affecting the catalytic domain (OR 13.9, 1.9-612; p=0.002). In the UK Biobank cohort, loss-of-function ATG7 variants increased the risk of cirrhosis and hepatocellular carcinoma (OR 3.30, 1.1-7.5 and OR 12.30, 2.6-36, respectively; p<0.001 for both). The low-frequency loss-of-function p.V471A variant (rs36117895 T>C) was also associated with severe NAFLD in the clinical cohort (OR=1.7, 1.2-2.5; p=0.003), predisposed to hepatocellular ballooning (p=0.007) evolving to fibrosis in a Liver biopsy cohort (n=2268), and was associated with liver injury in the UK Biobank (AST levels, p<0.001), with a larger effect in severely obese individuals where it was linked to hepatocellular carcinoma (p=0.009). ATG7 protein localized to periportal hepatocytes, more so in the presence of ballooning. In the Liver Transcriptomic cohort (n=125) ATG7 expression correlated with suppression of the TNFα pathway, which was conversely upregulated in p.V471A carriers. Conclusions: We identified rare and low-frequency ATG7 loss-of-function variants as modifiers of NAFLD progression by impairing autophagy and facilitating ballooning and inflammation. Lay summary: •We found that rare mutations in a gene called autophagy related (ATG7) increase the risk of developing severe liver disease in individuals with dysmetabolism. •These mutations cause an alteration in protein function and impairment of self-renewal of cellular content, leading to liver damage and inflammation.
English
NAFLD; NASH; autophagy; genetics; liver fibrosis;
Settore MED/09 - Medicina Interna
Articolo
Esperti anonimi
Pubblicazione scientifica
Goal 3: Good health and well-being
   Liver Investigation: Testing Marker Utility in Steatohepatitis
   LITMUS
   EUROPEAN COMMISSION
   777377
set-2022
8-apr-2022
Elsevier
77
3
596
606
11
Pubblicato
Periodico con rilevanza internazionale
https://www.sciencedirect.com/science/article/pii/S0168827822002070?via=ihub#!
pubmed
crossref
datacite
Aderisco
info:eu-repo/semantics/article
Rare ATG7 genetic variants predispose patients to severe fatty liver disease / G.A. Baselli, O. Jamialahmadi, S. Pelusi, E. Ciociola, F. Malvestiti, M. Saracino, L. Santoro, A. Cherubini, P. Dongiovanni, M. Maggioni, C. Bianco, F. Tavaglione, A. Cespiati, R.M. Mancina, R. D'Ambrosio, V. Vaira, S. Petta, L. Miele, U. Vespasiani-Gentilucci, A. Federico, J. Pihlajamaki, E. Bugianesi, A.L. Fracanzani, H.L. Reeves, G. Soardo, D. Prati, S. Romeo, L.V. Valenti. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 77:3(2022 Sep), pp. 596-606. [10.1016/j.jhep.2022.03.031]
open
Prodotti della ricerca::01 - Articolo su periodico
28
262
Article (author)
si
G.A. Baselli, O. Jamialahmadi, S. Pelusi, E. Ciociola, F. Malvestiti, M. Saracino, L. Santoro, A. Cherubini, P. Dongiovanni, M. Maggioni, C. Bianco, F...espandi
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0168827822002070-main (2).pdf

accesso aperto

Descrizione: Journal Pre-proof
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 11.17 MB
Formato Adobe PDF
11.17 MB Adobe PDF Visualizza/Apri
1-s2.0-S0168827822002070-main(1).pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.06 MB
Formato Adobe PDF
2.06 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/926557
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 39
social impact